Ascendiant Capital maintains Lucid Diagnostics at Buy

  • Investing.com
Ascendiant Capital maintains Lucid Diagnostics at Buy

An Ascendiant Capital analyst maintained Lucid Diagnostics (NASDAQ: LUCD) at Buy and a price target of $10.00 from a prior price target of $11.00.

Prior to this rating, Lucid Diagnostics had 5 buy ratings, 0 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Lucid Diagnostics, click here. For more news on Lucid Diagnostics, click here.

Lucid Diagnostics's stock price closed at $1.28. They are up 0% in the last month and down -54.29% in the last 12 months.

According to Investing Pro, Lucid Diagnostics's fair value is $1.44, an upside of 12.54%. Lucid Diagnostics's fair value comes with a high degree of uncertainty, according to InvestingPro.

Check out Lucid Diagnostics's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100